Gyre Therapeutics Inc
GYRE7.260USD
+0.070+0.97%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
659.86MMarket Cap
97.53P/E TTM
More Details of Gyre Therapeutics Inc Company
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
Gyre Therapeutics Inc Info
Ticker SymbolGYRE
Company nameGyre Therapeutics Inc
IPO dateApr 12, 2006
CEOZhang (Ping)
Number of employees574
Security typeOrdinary Share
Fiscal year-endApr 12
Address12770 High Bluff Drive, Suite 150
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18585677770
Websitehttps://www.gyretx.com/
Ticker SymbolGYRE
IPO dateApr 12, 2006
CEOZhang (Ping)
Company Executives of Gyre Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.84M
-3.64%
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
+7.69%
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Mr. Ping Zhang
Mr. Ping Zhang
Executive Chairman of the Board, Interim Chief Executive Officer
Executive Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. Gordon G. Carmichael, Ph.D.
Mr. Gordon G. Carmichael, Ph.D.
Independent Director
Independent Director
--
--
Dr. Renate Parry, Ph.D.
Dr. Renate Parry, Ph.D.
Independent Director
Independent Director
--
--
Dr. Dan Weng
Dr. Dan Weng
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.84M
-3.64%
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
+7.69%
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
GNI Group Ltd
80.07%
Luo (Ying)
3.13%
Ma (Songjiang)
3.12%
The Vanguard Group, Inc.
1.27%
Ye (Weiguo)
0.79%
Other
11.63%
Shareholders
Shareholders
Proportion
GNI Group Ltd
80.07%
Luo (Ying)
3.13%
Ma (Songjiang)
3.12%
The Vanguard Group, Inc.
1.27%
Ye (Weiguo)
0.79%
Other
11.63%
Shareholder Types
Shareholders
Proportion
Corporation
80.07%
Individual Investor
7.06%
Investment Advisor
2.21%
Investment Advisor/Hedge Fund
0.86%
Research Firm
0.24%
Pension Fund
0.08%
Hedge Fund
0.04%
Bank and Trust
0.02%
Other
9.42%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
122
3.38M
3.72%
+276.11K
2025Q2
124
82.04M
93.13%
+8.95M
2025Q1
126
82.96M
94.19%
+9.94M
2024Q4
117
71.62M
76.58%
-277.10K
2024Q3
117
71.44M
76.41%
-69.01K
2024Q2
108
71.18M
81.40%
+2.80M
2024Q1
95
70.73M
80.87%
+2.43M
2023Q4
101
67.57M
93.09%
+2.43M
2023Q3
124
846.01K
34.20%
-1.22M
2023Q2
137
853.88K
34.77%
-909.13K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
GNI Group Ltd
72.77M
80.12%
+8.77M
+13.70%
Mar 12, 2025
Luo (Ying)
2.84M
3.13%
--
--
Sep 06, 2024
Ma (Songjiang)
2.84M
3.12%
-107.21K
-3.64%
Mar 12, 2025
The Vanguard Group, Inc.
1.15M
1.27%
+53.22K
+4.85%
Jun 30, 2025
Ye (Weiguo)
700.00K
0.77%
+50.00K
+7.69%
Apr 01, 2025
BlackRock Institutional Trust Company, N.A.
765.74K
0.84%
+258.81K
+51.05%
Jun 30, 2025
Geode Capital Management, L.L.C.
401.71K
0.44%
+89.39K
+28.62%
Jun 30, 2025
State Street Investment Management (US)
177.77K
0.2%
+48.99K
+38.05%
Jun 30, 2025
SBI Securities Co., Ltd.
232.30K
0.26%
+108.67K
+87.90%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
129.42K
0.14%
+18.00K
+16.16%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Morningstar Small-Cap Value ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Broad Market ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Morningstar Small-Cap ETF
0%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
View more
iShares Morningstar Small-Cap Value ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
iShares Morningstar Small-Cap ETF
Proportion0%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Date
Type
Ratio
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
Oct 30, 2023
Merger
15→1
FAQs
Who are the top five shareholders of Gyre Therapeutics Inc?
The top five shareholders of Gyre Therapeutics Inc are:
GNI Group Ltd holds 72.77M shares, accounting for 80.12% of the total shares.
Luo (Ying) holds 2.84M shares, accounting for 3.13% of the total shares.
Ma (Songjiang) holds 2.84M shares, accounting for 3.12% of the total shares.
The Vanguard Group, Inc. holds 1.15M shares, accounting for 1.27% of the total shares.
Ye (Weiguo) holds 700.00K shares, accounting for 0.77% of the total shares.
GNI Group Ltd holds 72.77M shares, accounting for 80.12% of the total shares.
Luo (Ying) holds 2.84M shares, accounting for 3.13% of the total shares.
Ma (Songjiang) holds 2.84M shares, accounting for 3.12% of the total shares.
The Vanguard Group, Inc. holds 1.15M shares, accounting for 1.27% of the total shares.
Ye (Weiguo) holds 700.00K shares, accounting for 0.77% of the total shares.
What are the top three shareholder types of Gyre Therapeutics Inc?
The top three shareholder types of Gyre Therapeutics Inc are:
GNI Group Ltd
Luo (Ying)
Ma (Songjiang)
GNI Group Ltd
Luo (Ying)
Ma (Songjiang)
How many institutions hold shares of Gyre Therapeutics Inc (GYRE)?
As of 2025Q3, 122 institutions hold shares of Gyre Therapeutics Inc, with a combined market value of approximately 3.38M, accounting for 3.72% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -89.40%.
What is the biggest source of revenue for Gyre Therapeutics Inc?
In --, the -- business generated the highest revenue for Gyre Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
